A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm, Hitinder S

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. [electronic resource] - Circulation. Cardiovascular interventions Jun 2009 - 230-6 p. digital

Publication Type: Journal Article; Meta-Analysis

1941-7632

10.1161/CIRCINTERVENTIONS.108.847996 doi


Abciximab
Aged
Angioplasty, Balloon, Coronary--adverse effects
Antibodies, Monoclonal--adverse effects
Eptifibatide
Female
Hemorrhage--chemically induced
Humans
Immunoglobulin Fab Fragments--adverse effects
Male
Middle Aged
Myocardial Infarction--mortality
Odds Ratio
Peptides--adverse effects
Platelet Aggregation Inhibitors--adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors
Randomized Controlled Trials as Topic
Recurrence
Risk Assessment
Risk Factors
Thrombosis--etiology
Time Factors
Tirofiban
Treatment Outcome
Tyrosine--adverse effects